Table 2. Secondary endpoint results.
| Result | 95%CI | ||
|---|---|---|---|
| ORR (ITT, N=32) | CR+PR, n (%) | 26 (81.3%) | 63.6%, 92.8% |
| CR, n (%) | 3 (9.4%) | 2.0%, 25.0% | |
| PR, n (%) | 23 (71.9%) | 53.3%, 86.3% | |
| SD, n (%) | 4 (12.5%) | 3.5%, 29.0% | |
| PD, n (%) | 0 | ||
| Unknown, n (%) | 2 (6.3%) | 0.8%, 20.8% | |
| CBR (ITT, N=32) | CR+PR+SD≥6 months | 26 (81.3%) | 63.6%, 92.8% |
| DOR (ITT, N=26) | Median (months) | 9.8 | 5.82,11.60 |
| Event number | 19 (73.1%) | ||
| Censored number | 7 (26.9%) | ||
| No PD, no death | 7 (100.0%) | ||
| TTP (ITT, N=32) | Median (months) | 9.9 | 6.28,13.63 |
| OS (ITT, N=32) | Median (months) | NA | 22.64, NA |
| Mean (months) | 24.1 (0.75) | ||
| OS Event Number | 5 (15.6%) | ||
| OS Censored Number | 27 (84.4%) | ||
| No death | 27 (100.0%) | ||
| Median follow-up time (Months) | 20.1 | ||